Safety and Efficacy of a 90-day Vaginal Matrix Ring Containing Dapivirine and a Contraceptive in the Prevention of HIV-1 Infection in Women.

Trial Profile

Safety and Efficacy of a 90-day Vaginal Matrix Ring Containing Dapivirine and a Contraceptive in the Prevention of HIV-1 Infection in Women.

Planning
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs Dapivirine (Primary) ; Contraceptives
  • Indications HIV-1 infections; Pregnancy
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2014 New trial record
    • 08 May 2014 This trial will start in 2015, according to Janssen Media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top